COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Identification of Risk Factors Parkinson's Disease by Convergence Strategy (CONVERGENCE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03536104
Recruitment Status : Recruiting
First Posted : May 24, 2018
Last Update Posted : August 25, 2020
Information provided by (Responsible Party):
University Hospital, Lille

Brief Summary:
Using this convergence approach from a limited group of subjects with non-diseased controls, patients with Parkinson's disease or related diseases, we will be able to limit the number of potential genes of specific susceptibility to Parkinson disease. These genes will then be studied using a case-control genetic epidemiology approach. The risk of developing the disease will then be evaluated according to clinical, biological and environmental variables collected in Parkinson's subjects and healthy controls in the second group of subjects. The specificity of the genetic associations found will be evaluated in subjects with Parkinson's disease.

Condition or disease
Parkinson Disease

Layout table for study information
Study Type : Observational
Estimated Enrollment : 2220 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Identification of Risk Factors Parkinson's Disease by Convergence Strategy
Actual Study Start Date : March 25, 2009
Estimated Primary Completion Date : March 2024
Estimated Study Completion Date : March 2024

Resource links provided by the National Library of Medicine

This group will include "healthy" person.
Parkinson's patient
This group will include Parkinsonian patients
patients with a related disease.
This group will include patients with a related disease.

Primary Outcome Measures :
  1. Significant variations in the frequencies of gene polymorphisms and the risk of developing Parkinson's disease [ Time Frame: through study completion, an average of 10 years ]
    the frequency is measured according to biological and environmental variables modulating the risk of developing Parkinson's disease.

Biospecimen Retention:   Samples With DNA
serum, plasma, CSF

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Patients with Parkinson Disease compared to subjects at risk to develop Parkinson Disease and healthy controls

Inclusion Criteria:

  • Inclusion criteria for Parkinson's patients and "related diseases" controls:
  • Parkinsonian patients meeting the Gelb criteria
  • Patients with other neurodegenerative disease (such as other Parkinson syndrome or synucleopathies) meeting the criteria set out in Appendix 2 (Lewy Bodies dementia, Parkinson's disease with dementia, MultiSystem atrophy, Progressive Supranuclear Paralysis) , Amyotrophic Lateral Sclerosis, Restless Legs Syndrome, Alzheimer's Disease).
  • Woman of childbearing age having an effective means of contraception.
  • Informed consent signed by the subject or his legal representative.
  • For demented subjects coming for consultation or day hospitalization with an accompanying person, signature of the legal representative.

Criteria for inclusion of non-ill controls:

  • Absence of rest trembling, bradykinesia and stiffness
  • MMSE (Mini Mental State Examination) greater than 25
  • Woman of childbearing age having an effective means of contraception.
  • subject having signed the informed consent.
  • No family history of neurodegenerative disease that started before age 70. These controls will not present any Parkinsonian signs during the clinical evaluation. They may have functional disabilities whose cause is known and unrelated to a neurodegenerative disease with a cognitive function measurement greater than 25 in the MMSE test.

Exclusion Criteria:

  • Criteria for non-inclusion of patients:
  • Clinical criteria for exclusion of the diseases described
  • Participation in another therapeutic trial or in the exclusion period of a previous clinical trial.

Criteria for non-inclusion of non-ill controls:

  • Functional discomfort in daily life of unknown cause
  • MMSE less than 25
  • Participation in another therapeutic trial or in the exclusion period of a previous clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03536104

Layout table for location contacts
Contact: Alain DESTEE, MD,PhD

Layout table for location information
Hôpital Roger Salengro, CHRU de Lille Recruiting
Lille, France
Principal Investigator: Alain DESTEE, MD,PhD         
Sponsors and Collaborators
University Hospital, Lille
Layout table for investigator information
Principal Investigator: Alain DESTEE, MD, PhD University Hospital, Lille
Layout table for additonal information
Responsible Party: University Hospital, Lille Identifier: NCT03536104    
Other Study ID Numbers: 2008_0811
2008-A00219-46 ( Other Identifier: ID-RCB number, ANSM )
First Posted: May 24, 2018    Key Record Dates
Last Update Posted: August 25, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases